The renin-angiotensin system, in particular Angiotensin II (AngII), plays a significant role in the pathogenesis of hypertension in chronic kidney disease (CKD). Effects of chronic AT 1 receptor antagonism were investigated in a genetic hypertensive rat model of CKD, the Lewis polycystic kidney (LPK) rat.
Original article
The renin-angiotensin system (RAS) plays an important regulatory role in the development of hypertension and progression of chronic kidney disease (CKD). 1, 2 Angiotensin II (AngII) plays a detrimental role at the vasculature level, acting via AT 1 receptors to cause alterations of the nitric oxide (NO) pathway 3 and structural vascular remodeling. 4 Acting via AT 1 receptors, it can also induce remodeling of the arterial wall through smooth muscle growth 5, 6 and collagen deposition, 7 as shown in resistance arteries in essential hypertensive humans and rats. 8, 9 In addition, AngII has direct effects on the kidney contributing to proteinuria 10 and progressive loss of renal function in CKD. 1 We have previously established both large and resistance vessel structural and functional abnormalities in the Lewis polycystic kidney (LPK) rodent, 11, 12 a model of CKD due to a mutation in the Nek8 gene. 13, 14 Nek8 is a member of the nephronophthisis (NPHP) family, an autosomal recessive cystic kidney disease, which is the leading genetic cause of end-stage renal disease in children and young adults. 15 Consistent with a role for AngII in large-vessel vascular pathology, we have demonstrated in the LPK model that treatment with an angiotensin-converting enzyme inhibitor or AngII type 1 receptor antagonist can correct abnormal aortic stiffness, reduce aortic wall hypertrophy, and improve elastin fragmentation and calcification. 16, 17 Given the critical role of the resistance vasculature in the determination of high blood pressure in CKD, and the detrimental effects of AngII, we therefore sought to investigate the role of AT 1 receptors in the development of mesenteric artery pathophysiology using the LPK model. Animals were treated with the AT 1 receptor antagonist valsartan from 4 to 18 weeks of age. We hypothesized that valsartan treatment would ameliorate the detrimental structural, functional, and biomechanical vascular changes seen in these animals.
Mixed-sex LPK and age-matched control strain Lewis rats were obtained from the Animal Resource Centre, Western Australia, Australia. A total of 31 rats were used (untreated Lewis 4M/4F; valsartan-treated Lewis 4M/4F; untreated LPK 4M/4F; valsartan-treated LPK 4M/3F). All procedures were approved by the Institutional Animal Ethics Committee. Animals were treated from 4 to 18 weeks of age with valsartan 60 mg/kg/day (Diovan, Novartis, Switzerland) once daily, in up to 1-ml condensed milk, or with condensed milk only (controls).
Tail-cuff plethysmography and urine collection
Systolic blood pressure (SBP) and urine protein and creatinine levels were measured at 18 weeks, 72 hours prior to euthanasia. SBP was measured using tail-cuff plethysmography (ADInstruments, Bella Vista, NSW, Australia), 14 and urine samples were collected from animals over 24 hours while held individually in metabolic cages, during which animals were offered chow and water ad libitum, and water consumption was measured.
Tissue harvesting and biochemical analyses
Animals were deeply anesthetized with 5% isofluorane (Veterinary Companies of Australia, Blacktown, NSW, Australia) in 100% O 2 and decapitated. Trunk blood samples were collected in precooled ethylenediaminetetraacetic acid (EDTA) tubes (BD Microcontainer, Becton Dickinson, North Ryde, NSW, Australia) and centrifuged (3,000 rpm for 5 minutes at 4 °C). Plasma and urine were analyzed for biochemical parameters using an IDEXX VetLab analyzer (IDEXX Laboratories, Rydalmere, NSW, Australia). The mesenteric vasculature, kidneys, and heart were removed. The kidneys, heart, and left ventricle were weighed, and respective indices (KI, HI, LVI; %) were calculated as heart or kidney weight (g)/body weight (g) × 100. The LVI was calculated as left ventricle (g)/heart weight (g) × 100.
Second-order mesenteric artery segments were isolated for pressure myography and the remaining mesenteric vasculature was placed in 4% formalin for 24 hours, followed by 70% ethanol until further processing. The aorta from some animals in this study was also collected and contributed to another study. 16 As such, their phenotypic data contributed to previously published mean ± SEM data for some of the phenotypic parameters in Table 1 .
Pressure myography
Pressure myography protocols were undertaken as described previously 11 with full details provided as Supplementary Material.
After mounting in the pressure myograph (Living Systems Instrumentation, St. Albans, VT) and equilibration for 60 minutes at an intraluminal pressure of 60 mm Hg, mesenteric artery lumen and wall thickness dimensions were measured using the pressure myography video dimension analyzer. Vascular functional and structural investigations were then performed sequentially. All data were recorded using Spike 2/v7.07a software (Cambridge Electronic Design, Cambridge, UK). Results are expressed as mean ± SEM. Data were evaluated by 2-way ANOVA followed Bonferroni's post hoc analysis, except for urine protein and UPC, which were evaluated by unpaired t-test. Significance was defined as P ≤ 0.05. N value represents n across all data sets provided in the respective column; with range provided (minimum to maximum) where not all data could be collected from all animals. Within treatment strain effect: (a) untreated Lewis and LPK; (b) valsartan-treated Lewis and LPK. Within strain treatment effect: (c) untreated and valsartantreated Lewis; (d) untreated and valsartan-treated LPK. Abbreviations: BW, body weight; SBP, systolic blood pressure; HI, heart index; LVI, left ventricle index; KI, kidney index; nd, not determined; UPC, urine protein creatinine ratio; LPK, Lewis polycystic kidney rat.
Vascular function investigations.
Cumulative concentration-response curves to (i) phenylephrine (PE) and (ii) potassium chloride (KCl) were obtained to study vasoconstrictor mechanisms. Percentage vasoconstriction was calculated as % change in internal diameter, relative to the passive resting diameter.
After preconstriction with PE (10 −6 M), cumulative concentration-response curves to (i) the endotheliumdependent vasodilator acetylcholine (ACh) and (ii) endothelium-independent vasodilator sodium nitroprusside (SNP) were obtained to study endothelial integrity and endothelium-independent responses to an NO donor, respectively. Percentage vasorelaxation was calculated as percentage change in internal diameter, divided by change in internal diameter before and after PE (10 −6 M) constriction. 18 To further delineate vasorelaxation mechanisms, cumulative concentration-response curves to ACh were also obtained after the vessels had been preincubated in (i) either N-ω nitro-l-arginine-methyl-ester (l-NAME; 10 −4 ) alone or (ii) indomethacin (Indo 10 −5 M) and l-NAME.
GraphPad Prism (version 6, GraphPad Software, San Diego, CA) was used for curve fitting of concentrationresponse curves to PE, KCL, ACh, and SNP as per ref. 19 The pEC 50 value (negative logarithm of the 50% effective concentration [EC 50 ]) 20 and maximum response (R max ) were calculated for each animal from these curves. Values were then averaged for each cohort.
The differences between R max responses to ACh and ACh in the presence of l-NAME were considered the NO-dependent 21 component of the ACh-induced response; the ACh R max remaining in the presence of Indo + l-NAME combined was considered the endothelium-derived hyperpolarization (EDH) 22 component of the response. The difference between responses to ACh in the presence of Indo + l-NAME and l-NAME were considered the prostanoid component of the ACh-induced response.
Vascular structure investigations. After experimental protocols, vessels were deactivated by superfusion with Ca 2+ -free Krebs solution containing 10 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) for 20 minutes. Intraluminal pressure was increased incrementally via the servo-controlled pump from 3 to 180 mm Hg, and lumen and wall thickness dimensions were measured using the video dimension analyzer. Media cross-sectional area (MCSA), stress, strain, and elastic modulus were calculated for each animal individually. Formulae are provided in Supplementary Material.
Histology
After paraffin embedding and sectioning (5 µm), sections were mounted on glass slides and stained for collagen deposition and smooth muscle cell nuclei with Martius scarlet blue (MSB), for elastin with Shikata's Orcein and for calcification using Alizarin Red and Von Kossa (VK). 23, 24 Images were acquired at ×20 magnification under bright-field microscopy (Zeiss 1 Axiovision, Carl Zeiss, Germany). Histological stain analysis is provided in Supplementary Material.
Statistical analysis
Analysis was performed using IBM Statistical Package for the Social Sciences (v22, SPSS; Chicago, IL). All results are expressed as mean ± SEM. Preliminary univariate general linear model analysis of variance was performed to identify potential sex effects and unless significant, are not otherwise noted. Data were tested for homogeneity of variance (Levene's test), normality (Kolmogorov-Smirnov test), and skewness and kurtosis. If assumptions were met, 2-way analysis of variance (ANOVA) was performed, testing for strain and treatment effects and their interactions followed by Bonferroni post hoc analysis to investigate significant differences between groups when indicated. Data that did not meet assumptions of normality were analyzed post hoc with a Dunnett's T3 test. If a sex effect was identified on preliminary analysis, 2-way ANOVA was performed testing for strain (further defined by sex) and treatment effects.
Urine protein values less than 0.05 g/l were excluded, and corresponding UPC values were also removed. As such, no determinations were made for Lewis samples, and LPK urine protein and UPC (untreated vs. treated) were evaluated by unpaired t-test.
Two-way ANOVA with Bonferroni's post hoc analysis was used to evaluate concentration-response curves, as well as for strain, treatment and pharmacological effects for percentage contribution to vasorelaxation (NO; EDH; prostanoid). Significance was P ≤ 0.05 in all tests.
RESULTS

Baseline morphometric and biochemical parameters
Body and tissue weights, and plasma and urine analyses are provided in Table 1. LPK weighed less than Lewis, and male Lewis animals weighed more than females irrespective of treatment. SBP was elevated in LPK relative to Lewis, which valsartan treatment reduced but did not normalize. HI, LVI KI, plasma urea, and creatinine were elevated in LPK relative to Lewis. Treated LPK had lower KI values than untreated LPK. Urine analysis revealed lower urine creatinine values in LPK relative to Lewis, but there was no treatment effect. Urine protein was elevated in LPK, and while there was a trend toward reduction after treatment, this was not significant (P = 0.0647). Water intake was increased in untreated LPK compared with untreated Lewis, and valsartan treatment significantly reduced water intake in the LPK, such that it was no longer different to Lewis in either cohort (Table 1) .
Resistance vessel morphology
Untreated LPK demonstrated significantly smaller internal and external diameter values and increased wall thickness and wall-lumen ratio compared with untreated Lewis (Table 2 ). In LPK, valsartan treatment increased internal diameter and reduced wall thickness and wall-lumen ratio, such that these 2 latter parameters were not significantly different to Lewis. There was no strain or treatment effect for MCSA. Sex effects revealed that untreated LPK males had significantly smaller wall thickness values than LPK females (males vs. females: 44.63 ± 2.39 vs. 61.75 ± 0.50 µm, P = 0.005).
Vascular function investigations
Constriction. Untreated LPK PE concentrationresponse curves were significantly shifted to the left relative to untreated Lewis and treated LPK ( Figure 1A ). The untreated LPK KCl concentration-response curve was also Second-order mesenteric artery structural parameter data were obtained at 60 mm Hg following Ca 2+ -free superfusion. Results are expressed as mean ± SEM. Data were evaluated by 2-way ANOVA followed Bonferroni's post hoc analysis. Nonparametric data (wall-lumen ratio) underwent post hoc analysis using a Dunnett's T3 test. N value represents n across all data sets provided in the respective column. Significance was defined as P ≤ 0. significantly left shifted relative to treated LPK ( Figure 1B) ; however, this was not accompanied by changes in concentration-response curve parameters.
Endothelium-dependent and endothelium-independent vasorelaxation. Untreated LPK had impaired relaxation: the endothelium-dependent ACh concentration-response curve was significantly shifted to the right relative to untreated Lewis and treated LPK ( Figure 1C) . Accordingly, untreated LPK had significantly smaller ACh R max values than untreated Lewis and treated LPK (Table 3) . Overall, valsartan treatment normalized ACh-dependent vasorelaxation in LPKs, improving the pEC 50 value compared to untreated animals ( Table 3) .
The endothelium-independent SNP concentrationresponse curves in untreated and treated LPK were not significantly different from untreated and treated Lewis ( Figure 1D ). There were no alterations in SNP concentration-response curve parameters (Table 3) .
Vasorelaxation mechanism investigations.
Valsartan treatment in LPK resulted in vasorelaxation responses comparable with Lewis. Relative to control ACh responses, preincubation with l-NAME reduced the ACh R max in untreated and treated Lewis, and treated LPK (Table 3) . Preincubation with Indo + l-NAME resulted in a reduction in ACh R max values relative to the ACh response for all treatment groups and strains. In untreated LPK, the ACh R max following preincubation with Indo + l-NAME was significantly smaller than preincubation with l-NAME alone (Table 3) . Untreated LPK also had significantly smaller ACh R max values after preincubation with l-NAME, relative to untreated Lewis and treated LPK, respectively, and significantly smaller ACh R max values after preincubation with Indo + l-NAME, relative to untreated Lewis. These changes were not accompanied by alterations in the pEC 50 (Table 3) .
Vasorelaxation component investigations.
When the relative contribution of each vasorelaxation pathway was assessed, the percentage contribution to ACh R max by NO was increased in treated LPK, relative to untreated LPK, while the percentage contribution to ACh R max by prostanoids was reduced, such that it was no longer significantly different to the Lewis animals ( Figure 2 ). The percentage contribution to ACh R max by EDH was less in untreated LPK relative to untreated Lewis controls, but this difference was not evident in treated animals.
Resistance artery stiffness
Regardless of treatment group, LPK pressure-diameter curves were lower relative to Lewis. After treatment, the LPK pressure-diameter curve was significantly higher relative to untreated LPK ( Figure 3A) . Initial EC 50 values are provided in Supplementary Material. Results are expressed as mean ± SEM. Data were evaluated by 2-way ANOVA followed by Bonferroni's post hoc analysis. Nonparametric data (ACh R max and ACh [+ Indo + l-NAME] R max ) underwent post hoc analysis using a Dunnett's T3 test. N value represents n across all data sets provided in the respective column. Significance was defined as P ≤ 0.05. Within treatment strain effect: (a) untreated Lewis and LPK; (b) valsartan-treated Lewis and LPK. Within strain treatment effect: (c) untreated and valsartan-treated Lewis; (d) untreated and valsartan-treated LPK. Within strain pharmacological agent effect: (e) between ACh and ACh in the presence of (+) l-NAME; (f) between ACh and ACh in the presence of Indo and l-NAME; (g) between ACh in the presence of l-NAME and ACh in the presence of Indo and l-NAME. Abbreviations: LPK, Lewis polycystic kidney rat; PE, phenylephrine; KCl, potassium chloride; ACh, acetylcholine; SNP, sodium nitroprusside; l-NAME, N-ω nitro-l-arginine methyl ester at 10 −4 M; Indo, indomethacin at 10 −5 M; pEC 50 , negative logarithm of the EC 50 (effective concentration at 50%); R max , maximum response.
The stress-strain curves and the corresponding slope of elastic modulus vs. stress calculations for untreated LPK were significantly shifted to the left and had larger slope of elastic modulus vs. media stress values, respectively, relative to untreated Lewis ( Figure 3B,C) . Treatment shifted Lewis and LPK stress-strain curves to the right, relative to their corresponding untreated controls. This was not accompanied by significant changes in the slope of elastic modulus vs. media stress values; however, the slope in treated LPK was no longer significantly different to treated Lewis.
Resistance vessel composition
Representative images of Lewis and LPK images are provided in Figure 4 . Valsartan treatment significantly reduced collagen density in the LPK such that it was no longer significantly different to Lewis (Table 4 ). As such, collagen/elastin ratios were also significantly reduced by treatment in the LPK. A sex effect was noted, with untreated male LPK having significantly higher collagen/elastin ratio than untreated female LPK (males vs. females: 18.57 ± 1.21 vs. 3.12 ± 1.03, P = 0.005). No strain or treatment effect was identified for nuclear density, number of nuclei/μm 2 , elastin, or calcium density.
DISCUSSION
In this study, we report for the first time that chronic treatment with an AT 1 receptor antagonist improves detrimental vascular structural, functional, and biomechanical properties in the mesenteric resistance vasculature of a rodent model of CKD. These results support the key role played by AngII in the pathogenesis of vascular changes associated with CKD. 25 A primary finding was that AT 1 receptor antagonism significantly improved the degree of eutrophic inward remodeling, reducing wall thickness and wall-lumen ratio values in the LPK to levels comparable with Lewis controls. While these changes occurred alongside reduced blood pressure, it is important to note that inhibitors of the RAS have been shown to improve small artery structure to a greater degree than other anti-hypertensives, despite similar blood pressure reductions, 26 suggesting the effect is partly independent of the hemodynamic response and likely mediated by the direct prevention of AngII's cell proliferative and proinflammatory activities.
Untreated LPK arteries exhibited increased stiffness, as shown by the leftward shift of the stress-strain curve and less steep pressure-diameter curve gradient. In addition, the slope of elastic modulus vs. media stress values, an indicator of intrinsic stiffness independent of vessel geometry, 27 was increased, consistent with the increase in collagen density and collagen/elastin ratio. AT 1 receptors are linked to arterial stiffness, having been shown to induce smooth muscle growth 5, 6 and collagen deposition. 7 In the LPK treatment with valsartan improved compliance and reduced collagen deposition in the artery wall; however, it did not normalize the tissue, and given that the uremic state is in itself able to exert a detrimental effect on the vascular wall 18 without recovery of renal function, any further improvement of arterial compliance may be difficult to achieve.
Our investigation of the composition of the arterial wall also assessed elastin and calcification, which, consistent with our previous findings, 11 showed no difference from the control strain. This is in stark contrast to what we and others have previously described in large vessels in association with CKD. 12, 28 Elastin degradation is strongly associated with vascular calcification 28 and given that mesenteric arteries have a very small percentage of elastin (average of ~10% of Lewis rats), this would reduce the likelihood of calcification, relative to vessels such as the aorta.
In addition to structure and biomechanics, AT 1 receptor antagonism improved functional abnormalities present in the LPK. Valsartan ameliorated the enhanced constrictor effect to PE, returning it to a response comparable to the Lewis controls, and interestingly, valsartan-treated LPK were less sensitive to KCl-a phenomena that was also observed in hypertensive and diabetic conditions. 29 The underlying ion channels involved and mechanism contributing to this finding are unknown, and further studies are warranted to determine whether it is the antihypertensive effects of valsartan treatment, as opposed to its AT 1 receptor antagonism, which have affected the KCl-mediated response in the LPK rat.
The present study found impaired endothelium-dependent relaxation in untreated LPK resistance vessels, which is in accordance with previous investigations of renovascular hypertensive and autosomal-dominant polycystic kidney disease patients. 30, 31 Incubation with a NO synthase (NOS) inhibitor significantly attenuated ACh-induced relaxation in the Lewis and treated LPK, but not in the untreated LPK. This suggests that valsartan treatment may protect LPK from developing defective NOS activity, and perhaps reduce ROS and therefore preserve NO bioavailability .
31
Our investigation into vasorelaxation mechanisms further revealed an upregulation of the prostanoid contribution, and downregulation of the EDH contribution, to ACh-mediated vasodilation in the LPK. Treatment with valsartan improved the EDH response and corrected the prostanoid component, alongside producing an increase in the NO contribution to ACh R max . This correction is consistent with AngII being able to drive impaired EDH-mediated vasorelaxation 32 and upregulate prostaglandin production in various tissues. 33 It is also possible that valsartan treatment increased the bioavailability of active vs. inactive endothelial NOS (eNOS), as the activity levels of eNOS have been shown to be impaired in another rodent cystic kidney model. 34 There may have also been a blood pressure-dependent component to the improvement, as reduced stress against the arterial wall will improve endothelium integrity.
A consideration in interpreting the results of this study is the impact of valsartan treatment on sympathetic nerve activity (SNA) to the vasculature. We have previously provided evidence that acute AT 1 receptor blockade improves baroreflex and peripheral chemoreflex control of SNA; however, it does not reduce the otherwise increased level of tonic level of activity. 35 Long-term AT 1 blockade may however have an impact on sympathetic tone, which is known to impact both endothelial function and vascular structure. 36 Further chronic treatment studies are required to validate this relationship.
A final consideration of the present study is that despite the notable reduction in blood pressure, AT 1 receptor antagonism did not provide any marked renoprotective effects, which is consistent with our previous studies. 16 There was a small reduction in cystic kidney size, and interestingly, valsartan treatment decreased water intake in LPK, an effect that has been noted previously in a mouse model of highsalt-diet-induced hypertension. 37 This response may be due to valsartan's ability to affect intracerebroventricular AngII and therefore influence polydipsia centrally. 38 In summary, our data show that in a rat model of CKD, valsartan improves altered mesenteric artery structural, functional, and biomechanical properties, likely via directly blocking the actions of AngII, which promote vascular injury, 39 complemented by its blood pressurelowering effects. The present investigations highlight the importance of AngII in driving resistance vascular dysfunction and provide insight as to how chronic treatment with AT 1 receptor blockers can have substantial vascular benefits that extend beyond their general therapeutic use in CKD.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of Hypertension. Collagen density (%) 18.0 ± 1.3 33.6 ± 4.7 a 13.4 ± 1.1 21.9 ± 3. Elastin density (%) 8.6 ± 2.3 6.8 ± 2.5 7.4 ± 2.4 6.8 ± 1.8
Collagen/elastin ratio 2.6 ± 0.4 9.7 ± 3.2 a 2.7 ± 0.5 4.0 ± 0.9
Calcium density (%) 0.01 ± 0.01 0.06 ± 0.03 0.01 ± 0.01 0.00 ± 0.00
Results are expressed as mean ± SEM. Data were evaluated by 2-way ANOVA followed by Bonferroni's post hoc analysis. Nonparametric data (elastin density and collagen/elastin ratio) underwent post hoc analysis using a Dunnett's T3 test. N value represents n across all data sets provided in the respective column. Significance was defined as P ≤ 0.05. Within treatment strain effect: (a) untreated Lewis and LPK; (b) valsartan-treated Lewis and LPK. Within strain treatment effect; (c) untreated and valsartan-treated Lewis; (d) untreated and valsartan-treated LPK. Abbreviation: LPK, Lewis polycystic kidney rat.
